Verinata Health said this week that it has raised around $46.5 million in a Series C financing round, with an additional $2 million expected to close by the end of the month.

It plans to use the proceeds to fund continued research and development and the eventual commercialization of its sequencing-based noninvasive prenatal diagnostic test for chromosomal abnormalities, such as trisomy 21.

The funding round was led by existing investors Mohr Davidow Ventures, Sutter Hill Ventures, and Alloy Ventures.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.